Metropolitan Life Insurance Co NY Purchases 1,855 Shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA)

Metropolitan Life Insurance Co NY lifted its position in shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) by 5.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,240 shares of the biotechnology company’s stock after buying an additional 1,855 shares during the period. Metropolitan Life Insurance Co NY’s holdings in Iovance Biotherapeutics were worth $678,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Iovance Biotherapeutics by 46.3% in the 2nd quarter. Vanguard Group Inc. now owns 8,491,841 shares of the biotechnology company’s stock worth $208,220,000 after buying an additional 2,688,963 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Iovance Biotherapeutics by 72.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 6,023,903 shares of the biotechnology company’s stock worth $147,706,000 after acquiring an additional 2,531,169 shares in the last quarter. State Street Corp lifted its holdings in shares of Iovance Biotherapeutics by 39.1% in the 3rd quarter. State Street Corp now owns 4,758,219 shares of the biotechnology company’s stock worth $86,600,000 after acquiring an additional 1,336,353 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Iovance Biotherapeutics by 48.2% in the 2nd quarter. Bank of America Corp DE now owns 3,084,339 shares of the biotechnology company’s stock worth $75,627,000 after acquiring an additional 1,002,500 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Iovance Biotherapeutics by 178.0% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,264,096 shares of the biotechnology company’s stock worth $30,996,000 after acquiring an additional 809,398 shares during the last quarter. 98.10% of the stock is currently owned by institutional investors.

Several research firms recently commented on IOVA. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a report on Thursday, November 21st. Stifel Nicolaus began coverage on shares of Iovance Biotherapeutics in a research note on Monday, September 30th. They issued a “buy” rating and a $27.00 price target for the company. BidaskClub raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday. ValuEngine lowered shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Finally, B. Riley set a $28.00 price objective on Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Friday, August 16th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $29.27.

NASDAQ:IOVA opened at $25.62 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.61 and a current ratio of 10.61. Iovance Biotherapeutics Inc has a fifty-two week low of $7.26 and a fifty-two week high of $26.59. The firm has a market cap of $3.12 billion, a PE ratio of -20.17 and a beta of 1.99. The business has a 50 day moving average price of $22.27 and a 200-day moving average price of $21.33.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.01). Research analysts predict that Iovance Biotherapeutics Inc will post -1.5 EPS for the current year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Read More: Are sell-side analysts objective?

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.